Oncology patients have been heavily impacted by the ongoing SARS-CoV-2 pandemic. With thousands of tissue biopsies being delayed and patients postponing clinic visits, increasing access to Circulating tumour DNA (ctDNA) testing for targeted treatment selection offers another option for academic and community hospitals.
Illumina and Canexia Health invite you to a virtual discussion, on topics such as those listed below, with a panel of experts:
Your email address is never shared with third parties.